nejm tirzepatide New in the January 30, 2025, issue of NEJM: for Heart Failure and Obesity (SUMMIT trial) https://nej.md/4hRGaTY Continuation of Oral Anticoagulation during TAVI (POPular PAUSE TAVI trial) https://nej.md/3XllHys Lentiviral Gene Therapy In the two SURMOUNT-OSA trials,

When considering medications like Ozempic for patients with high blood pressure, our approach includes: Ongoing Support: Regular check-ins to track your progress, manage any side effects, and make necessary adjustments to your treatment plan

Patients experiencing significant bloating may benefit from extending the time between dose increases, temporarily returning to a previously tolerated dose, or even holding a dose if symptoms are severe, under healthcare provider guidance

No matter the direction, working with a healthcare provider helps you stay safe and make the most of your progress

But these side effects are very rare

Patients who eat sugary foods while on the medication often deal with: These reactions are not a sign that the medication is failing

The persuasive factor in oral tirzepatide is sustainability